Medtronic plc

Medtronic plc

Medtronic plc was founded in 1949 in Minneapolis by electrical engineer Earl Bakken and his brother-in-law Palmer Hermundslie. Bakken invented the first wearable external pacemaker in 1957, establishing the company's cardiac-care dominance. The firm reincorporated in Ireland in 2015 through a tax inversion merger with Covidien, but maintains operational headquarters outside Minneapolis (per public record). The firm invests across multiple medical-device categories: cardiac rhythm management, neuromodulation, surgical robotics, and diabetes management. Medtronic deploys capital through internal R&D — spending $2.8B on R&D in fiscal 2024 — and through acquisitions such as the $738M purchase of EOFlow in 2023 for insulin-patch-pump technology (per Medtronic press release, 2023). Portfolio holdings are not applicable to a publicly traded product company, but its operating segments span over 150 countries. Medtronic employs roughly 95,000 people globally, with principal offices in Minneapolis, Dublin, and major manufacturing sites in Puerto Rico, China, and Mexico. A dated operational event: February 2024 — Medtronic spun out its Patient Monitoring and Respiratory Interventions businesses into a separate company named NewCo, signaling a strategic shift toward focus on core high-growth segments (per Medtronic, February 2024). The company maintains a charitable foundation, the Medtronic Foundation, directed separately. What structurally differentiates Medtronic from a typical family office or asset manager is its status as a publicly traded entity with product revenue — not investment returns — as its primary financial engine. The founding Bakken family no longer holds majority control or management roles, but the company's governance retains a board overseen by independent directors and annual shareholder votes, a regulatory posture distinct from private capital pools.